Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 3/20 | 0.39 |
| ▸ | TYMP | P19971 | 5/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12740554 | 1.00 | ALDH1A1 (0.40) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL14639895 | 0.88 | ALDH1A1 (0.43) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL26735099 | 0.88 | ALDH1A1 (0.40) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL12087530 | 0.85 | TK1 (0.40) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL12015161 | 0.85 | TK1 (0.40) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL12590097 | 0.85 | TK1 (0.40) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL19884483 | 0.84 | TK1 (0.38) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL26735228 | 0.82 | TYMP (0.39) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL24263989 | 0.81 | TK1 (0.46) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL5996943 | 0.81 | TK1 (0.46) | ALDH1A1LMNAALBPOLBADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657049-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Matsuo, Masafumi (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9657050-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | Masafumi, Matsuo (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9243026-B2 | ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-26 | — | — | US | disclosed |
| US-20160002636-A1 | ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20140316123-A1 | ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-10-23 | — | — | US | disclosed |
| US-8624019-B2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20130090465-A1 | ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-11 | — | — | US | disclosed |
| US-7902160-B2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20110046360-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | Matsuo, Masafumi (JP) | 2011-02-24 | — | — | US | disclosed |
| US-20070082861-A1 | Ena nucleic acid drugs modifying splicing in mrna precursor | MASAFUMI MATSUO (JP) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090465-A1 | ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS | SNRPA, RBM17, SNRPA1 | ALDH1A1 2740/4885LMNA 145/4885ALB 4863/4885 |
| US-20110046360-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | SNRPA, RBM17, SNRPA1 | ALDH1A1 2027/4885LMNA 148/4885ALB 4853/4885 |
| US-20070082861-A1 | Ena nucleic acid drugs modifying splicing in mrna precursor | SNRPA, RBM17, SNRPA1 | ALDH1A1 2027/4885LMNA 148/4885ALB 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.